1. Phylogeny  
   Non‐receptor tyrosine‐protein kinase TYK2 is a member of the Janus kinase (JAK) family, which comprises four members—JAK1, JAK2, JAK3, and TYK2—that are evolutionarily conserved among vertebrates (argiriadi2012enablingstructurebaseddrug pages 10-11, azevedo2019nonreceptortyrosinekinases pages 1-3). Orthologs of TYK2 have been identified in a wide range of mammals, indicating that its essential role in cytokine receptor signaling arose early in metazoan evolution and has been maintained throughout vertebrate diversification (argiriadi2012enablingstructurebaseddrug pages 10-11, azevedo2019nonreceptortyrosinekinases pages 1-3). Within the human kinome, TYK2 is classified under the non‐receptor tyrosine kinase branch and, more specifically, among the JAK family members that share a conserved modular domain organization essential for mediating responses to cytokines and interferons (argiriadi2012enablingstructurebaseddrug pages 10-11, azevedo2019nonreceptortyrosinekinases pages 1-3).
2. Reaction Catalyzed  
   TYK2 catalyzes the phosphorylation of tyrosine residues by transferring the γ-phosphate from ATP to specific tyrosine residues on protein substrates (babon2014themolecularregulation pages 1-3). The overall chemical reaction can be represented by the generalized equation:  
     ATP + [protein]-L-tyrosine = ADP + [protein]-L-tyrosine-phosphate + H⁺,  
   which serves as the fundamental biochemical process underlying the activation of downstream signaling molecules in response to cytokine stimulation (babon2014themolecularregulation pages 1-3).
3. Cofactor Requirements  
   The catalytic activity of TYK2 requires the presence of divalent metal ion cofactors, with magnesium ions (Mg²⁺) being essential to properly coordinate ATP within the enzyme’s active site (min2015structuralandfunctional pages 1-2). The requirement for Mg²⁺ is consistent with the biochemical properties of most protein kinases, where the metal ion facilitates the correct positioning and stabilization of ATP to enable efficient phosphoryl transfer (min2015structuralandfunctional pages 1-2).
4. Substrate Specificity  
   TYK2 phosphorylates tyrosine residues that are principally located in the intracellular domains of cytokine receptor chains as well as on downstream signaling proteins such as STAT transcription factors (babon2014themolecularregulation pages 1-3). Although a well‐defined consensus sequence analogous to the RxRxxp[ST] motif seen in serine/threonine kinases has not been fully established for TYK2, its substrates tend to feature specific tyrosine residues that, when phosphorylated, function as binding sites for downstream signaling effectors including STAT1, STAT3, STAT4, and STAT6 (YaronBarir2024TheIntrinsicSubstrate pages 1-2). Peptide-array approaches and intrinsic substrate specificity studies indicate that the preference for tyrosine residues is a key determinant in recruiting the correct signaling partners during cytokine responses (YaronBarir2024TheIntrinsicSubstrate pages 1-2).
5. Structure  
   TYK2 is organized into a series of distinct domains that each contribute to its function in cytokine signaling. At the N-terminus, TYK2 contains a FERM (band 4.1, ezrin, radixin, moesin) domain, which is critical for binding to the cytoplasmic tails of cytokine receptors such as IFNAR1, IL12RB1, IL10RB, and IL13RA1 (argiriadi2012enablingstructurebaseddrug pages 10-11, karjalainen2016interactionsofjak2 pages 8-11). Adjacent to the FERM domain is an SH2-like domain; although it may not bind phosphotyrosine in the canonical fashion, it assists in stabilizing receptor interactions and ensuring proper spatial orientation within the signaling complex (argiriadi2012enablingstructurebaseddrug pages 10-11, karjalainen2016interactionsofjak2 pages 8-11).  
   Following the receptor-binding modules, TYK2 harbors a pseudokinase domain (often referred to as JH2) that, despite retaining an overall kinase fold and the capacity to bind ATP, lacks the full complement of catalytic residues typically required for phosphoryl transfer. This domain plays an essential regulatory role by modulating the activity of the adjacent catalytic tyrosine kinase domain (JH1) and by participating in intramolecular interactions that maintain TYK2 in an autoinhibited state under basal conditions (min2015structuralandfunctional pages 2-3, mingione2023allostericregulationand pages 1-3).  
   At its C-terminus, the JH1 domain is responsible for the actual phosphotransfer reaction. This catalytic domain adopts a classical bilobal structure with a small N-terminal lobe that includes the glycine-rich loop involved in ATP binding and a conserved lysine residue critical for proper ATP orientation, and a larger C-terminal lobe that houses the activation loop (A-loop) along with key motifs such as the HRD and DFG sequences, which are integral to catalytic efficiency and stabilization of the enzyme’s active conformation (min2015structuralandfunctional pages 2-3, mingione2023allostericregulationand pages 1-3). Key structural features, including hydrophobic spines and the C-helix, facilitate the conformational changes associated with activation and allosteric regulation, and these elements are vital for the transmission of regulatory signals from the pseudokinase to the kinase domain (mingione2023allostericregulationand pages 7-9).
6. Regulation  
   TYK2 is subject to multiple layers of regulation that ensure its activity is tightly controlled in response to extracellular signals. Cytokine binding to the receptor complex triggers receptor dimerization, which in turn promotes trans-phosphorylation of tyrosine residues within the activation loop of the catalytic kinase domain, thereby stabilizing the active conformation needed for effective substrate phosphorylation (babon2014themolecularregulation pages 1-3, min2015structuralandfunctional pages 2-3).  
   The pseudokinase domain exerts an autoinhibitory effect under resting conditions by engaging in intramolecular interactions that constrain the kinase domain’s activity; however, upon cytokine-induced receptor engagement and subsequent ATP binding to the pseudokinase domain, conformational changes are induced that relieve this autoinhibition and promote catalytic activation (li2017insightsontype pages 22-26, li2017insightsontypea pages 22-26). Additionally, TYK2 has been shown to negatively regulate STAT3 signaling by phosphorylating a specific tyrosine residue that is distinct from the residues involved in the primary activation of STAT proteins, thereby providing an additional level of control over downstream transcriptional responses (gerstenberger2020demonstrationofin pages 8-9, he2019selectivetyk2inhibitors pages 11-13).
7. Function  
   TYK2 plays a critical role as a mediator of cytokine and interferon signaling by associating with heterodimeric cytokine receptor complexes. In these complexes, one receptor chain (for example, IFNAR1, IL12RB1, IL10RB, or IL13RA1) is constitutively bound to TYK2, while a second receptor chain is associated with another JAK family member such as JAK1 or JAK2. Ligand binding to these receptor complexes initiates TYK2-dependent phosphorylation of the receptor chains, thereby creating docking sites for STAT transcription factors (argiriadi2012enablingstructurebaseddrug pages 10-11, azevedo2019nonreceptortyrosinekinases pages 1-3).  
   Following recruitment, STAT proteins (including STAT1, STAT3, STAT4, and STAT6) are phosphorylated by TYK2 (or the partnering JAK) and subsequently dimerize and translocate to the nucleus, where they modulate gene expression programs involved in cell growth, development, differentiation, and both innate and adaptive immunity (argiriadi2012enablingstructurebaseddrug pages 10-11, babon2014themolecularregulation pages 1-3). Moreover, TYK2 exerts a dual regulatory function by not only activating STAT family members but also by selectively attenuating STAT3 signaling through phosphorylation of a unique tyrosine residue distinct from the canonical activation sites (karjalainen2016interactionsofjak2 pages 8-11, babon2014themolecularregulation pages 1-3). TYK2 is expressed widely in immune cell populations including lymphocytes and myeloid cells, where its activity is central to the orchestration of antiviral responses and inflammation (min2015structuralandfunctional pages 2-3, mingione2023allostericregulationand pages 1-3).
8. Other Comments  
   Due to its central role in cytokine and interferon signaling, TYK2 has become an attractive target for therapeutic intervention in autoimmune and inflammatory disorders. Several small molecule inhibitors have been developed that target TYK2, with some compounds binding selectively to its pseudokinase domain to stabilize the autoinhibited conformation and thus reduce kinase activity (he2019selectivetyk2inhibitors pages 11-13, mingione2023allostericregulationand pages 7-9). Genetic polymorphisms and mutations within the TYK2 gene are associated with altered susceptibility to various autoimmune diseases, which may result from impaired receptor phosphorylation or dysregulated STAT activation due to perturbations in the pseudokinase‐kinase domain interface (li2017insightsontypeb pages 22-26, majeski2020theroleof pages 35-39). In addition, aberrant activation of TYK2 has been implicated in certain hematological malignancies where constitutive kinase activation drives pathological cell survival and proliferation (min2015structuralandfunctional pages 2-3, li2017insightsontypea pages 22-26). These clinical associations underscore the importance of ongoing drug discovery efforts aimed at modulating TYK2 activity while minimizing off-target effects on other JAK family members (he2019selectivetyk2inhibitors pages 11-13, majeski2020theroleof pages 39-43).
9. References
10. Argiriadi2012EnablingStructureBasedDrug pages 10-11
11. Azevedo2019NonReceptorTyrosineKinases pages 1-3
12. Babon2014TheMolecularRegulation pages 1-3
13. Karjalainen2016InteractionsOfJAK2 pages 8-11
14. Min2015StructuralAndFunctional pages 1-2
15. Min2015StructuralAndFunctional pages 2-3
16. Li2017InsightsOnType pages 22-26
17. Li2017InsightsOnTypeA pages 22-26
18. Li2017InsightsOnTypeB pages 22-26
19. Mingione2023AllostericRegulationAnd pages 1-3
20. Mingione2023AllostericRegulationAnd pages 7-9
21. He2019SelectivityTYK2Inhibitors pages 11-13
22. Gerstenberger2020DemonstrationOfIn pages 8-9
23. (Additional references are not included as they are not provided in the current context.)

References

1. (argiriadi2012enablingstructurebaseddrug pages 10-11): Maria A Argiriadi, Eric R Goedken, David Banach, David W Borhani, Andrew Burchat, Richard W Dixon, Doug Marcotte, Gary Overmeyer, Valerie Pivorunas, Ramkrishna Sadhukhan, Silvino Sousa, Nigel St Moore, Medha Tomlinson, Jeffrey Voss, Lu Wang, Neil Wishart, Kevin Woller, and Robert V Talanian. Enabling structure-based drug design of tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Structural Biology, 12:22-22, Sep 2012. URL: https://doi.org/10.1186/1472-6807-12-22, doi:10.1186/1472-6807-12-22. This article has 20 citations and is from a peer-reviewed journal.
2. (azevedo2019nonreceptortyrosinekinases pages 1-3): Ana Azevedo, Susana Silva, and José Rueff. Non-receptor tyrosine kinases role and significance in hematological malignancies. Tyrosine Kinases as Druggable Targets in Cancer, Sep 2019. URL: https://doi.org/10.5772/intechopen.84873, doi:10.5772/intechopen.84873. This article has 15 citations.
3. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
4. (gerstenberger2020demonstrationofin pages 8-9): Brian S. Gerstenberger, Mary Ellen Banker, James D. Clark, Martin E. Dowty, Andrew Fensome, Roger Gifford, Matthew C. Griffor, Martin Hegen, Brett D. Hollingshead, John D. Knafels, Tsung H. Lin, James F. Smith, and Felix F. Vajdos. Demonstration of in vitro to in vivo translation of a tyk2 inhibitor that shows cross species potency differences. Scientific Reports, Jun 2020. URL: https://doi.org/10.1038/s41598-020-65762-y, doi:10.1038/s41598-020-65762-y. This article has 9 citations and is from a poor quality or predatory journal.
5. (he2019selectivetyk2inhibitors pages 11-13): Xingrui He, Xiabin Chen, Hancheng Zhang, Tian Xie, and Xiang-Yang Ye. Selective tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opinion on Therapeutic Patents, 29:137-149, Jan 2019. URL: https://doi.org/10.1080/13543776.2019.1567713, doi:10.1080/13543776.2019.1567713. This article has 74 citations and is from a peer-reviewed journal.
6. (karjalainen2016interactionsofjak2 pages 8-11): A KARJALAINEN. Interactions of jak2 pseudokinase and kinase do-mains in health and disease. Unknown journal, 2016.
7. (li2017insightsontype pages 22-26): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
8. (li2017insightsontypea pages 22-26): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
9. (li2017insightsontypeb pages 22-26): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
10. (majeski2020theroleof pages 35-39): HE Majeski. The role of tyk2 in matrix stiffness-driven emt and metastasis. Unknown journal, 2020.
11. (majeski2020theroleof pages 39-43): HE Majeski. The role of tyk2 in matrix stiffness-driven emt and metastasis. Unknown journal, 2020.
12. (min2015structuralandfunctional pages 1-2): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
13. (min2015structuralandfunctional pages 2-3): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
14. (mingione2023allostericregulationand pages 1-3): Victoria R. Mingione, YiTing Paung, Ian R. Outhwaite, and Markus A. Seeliger. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. URL: https://doi.org/10.1042/bst20220940, doi:10.1042/bst20220940. This article has 19 citations and is from a peer-reviewed journal.
15. (mingione2023allostericregulationand pages 7-9): Victoria R. Mingione, YiTing Paung, Ian R. Outhwaite, and Markus A. Seeliger. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. URL: https://doi.org/10.1042/bst20220940, doi:10.1042/bst20220940. This article has 19 citations and is from a peer-reviewed journal.